



► **BIOTECH POOL**

Amy Fix
Dr. Louis Fries III
Dr. Glenn Gregory
NOVAVAX ANNOUNCES
MANAGEMENT PROMOTION



Dr. Glenn Gregory

Novavax, a clinical-stage vaccine company focused on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants, has made several promotions.

Amy Fix has been named senior VP, regulatory affairs. Ms. Fix joined Novavax in April 2013 as VP, regulatory affairs, and is responsible for regulatory strategy, regulatory operations, and interactions with international regulatory agencies, including the FDA, the European Medicines Agency, and a number of other global regulatory agencies.

Louis Fries III, M.D., has been named senior VP and chief medical officer. Dr. Fries joined Novavax in 2011 with more than 22 years of experience in clinical testing and development of human vaccines in academic, small biotech, and major biopharmaceutical environments.

The company named Dr. Gregory Glenn president, research and development. Dr. Glenn joined Novavax as its chief scientific officer in July 2010.

Dr. Diego Miralles
ADAPTIVE BIOTECHNOLOGIES NAMES
PRESIDENT OF ADAPTIVE THERAPEUTICS



Dr. Diego Miralles

Adaptive Biotechnologies, a leader in next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, has appointed Diego Miralles, M.D., as president of Adaptive Therapeutics.

Most recently, Dr. Miralles was the global head, Johnson & Johnson Innovation, where he established the Johnson & Johnson Innovation Centers, JLABS, and Janssen Healthcare Innovation.

Dr. Miralles is charged with building the therapeutics division of Adaptive and heading the company's efforts to leverage its best-in-class platform for identifying T- and B-cell receptors for use in therapies that will directly impact patient outcomes.

Dr. Bruce Roberts
VEDANTA BIOSCIENCES APPOINTS NEW
CHIEF SCIENTIFIC OFFICER

Vedanta Biosciences, which is pioneering the development of a new class of therapies designed



Dr. Bruce Roberts

to modulate the human microbiome, has appointed former Genzyme group VP, Bruce Roberts, Ph.D., as chief scientific officer.

Dr. Roberts has 30 years of experience in biotechnology and pharmaceutical drug discovery and development. He most recently served as head of neuroimmunology and immune-mediated disease research at Sanofi Genzyme where he directed preclinical efforts resulting in the introduction of therapeutic antibodies, gene therapies, cell therapies and small molecules into multiple clinical trials for the treatment of cancer, multiple sclerosis, and autoimmunity.

► **CRO POOL**

Francois Audibert
Steven Herne
BIOCLINICA EXPANDS EHEALTH SOLUTIONS'
STRATEGIC LEADERSHIP TEAM



Steven Herne

Bioclinica, a specialty clinical trials technology and services provider, has brought two industry experts on board to join its eHealth business segment leadership team.

Francois Audibert has been named VP for global consulting, responsible for data sciences, safety system, and process as well as the company's life-sciences big data strategy. Mr. Audibert was most recently VP of pharmacovigilance at HighPoint Solutions.

Steven Herne is charged with heading Bioclinica eHealth Solutions global commercial endeavors across all three divisions comprising eClinical, safety and regulatory, and financial lifecycle solutions. Mr. Herne was most recently chief commercial officer at ERT where he was an executive member of the global leadership team, responsible for creating and executing the long-term strategic growth plan across all business lines.

Faith Kolb
VERISTAT STRENGTHENS SENIOR
MANAGEMENT TEAM



Faith Kolb

Veristat, a full-service CRO, has appointed Faith Haines Kolb to the newly created position VP of biometrics. She joins Veristat with more than 20 years of experience leading operational teams and large-scale projects during periods of rapid growth

and international expansion for both large and small CROs. Most recently, she was the worldwide head of data management and biostatistics for Parexel's early phase group.

In her new role, she is responsible for leading the biostatistics and programming teams, as well as the data management and data standards groups at Veristat.

► **AGENCY POOL**

Jon Bircher
CELLO HEALTH NAMES CHIEF
COMMERCIAL OFFICER



Jon Bircher

Cello Health has appointed Jon Bircher as chief commercial officer, a new position aimed at building the brand positioning and proposition in the marketplace. He assumes responsibility for market positioning and reputation, as well as the commercialization of key cross-capability offerings. He joined Cello Health Consulting, formerly The MSI Consultancy, 10 years ago.

Charlie Buckwell
Simon Holt
Michel Nakache
MCCANN HEALTH STRENGTHENS
LEADERSHIP TEAM



Charlie Buckwell

McCann Health, the professional and consumer health and wellness global communications network, and part of McCann Worldgroup, has promoted Charlie Buckwell to president, Europe, Middle East & Africa (EMEA). Mr. Buckwell succeeds Michel Nakache, who is promoted to the newly created role of president, global clients unit. Mr. Buckwell continues to oversee McCann Complete Medical.



Michel Nakache

In addition, Simon Holt has been appointed to the newly created position of chief business strategy officer.

Mr. Holt, who joins the company from Novartis International, where he was global head public policy, also assumes leadership of McCann Health's Double Helix Consulting & Double Helix Discovery units, succeeding Mr. Buckwell. ^{PV}

(c) PharmaLinx LLC. Rights do not include promotional use. For distribution or printing rights, contact mwals@pharmavoices.com

FOR BONUS CONTENT
USE YOUR QR CODE READER
OR GO TO
bit.ly/PV0516-Pool



► PHARMA POOL

Sean Brynjelsen
SAGENT PHARMACEUTICALS
NAMES EXECUTIVE VP, BUSINESS
DEVELOPMENT

Sagent Pharmaceuticals, a provider of affordable pharmaceuticals to the hospital market, has hired Sean Brynjelsen as executive VP, business development. In this newly created role, Mr. Brynjelsen is charged with developing and executing a strategy to drive long-term growth through the acceleration of product licensing, acquisition of products and portfolios as well as the execution of other M&A activity. Most recently, he served as senior VP, global business development, for Akorn.

Marino Garcia
SYNERGY PHARMACEUTICALS APPOINTS
CHIEF STRATEGY OFFICER

Synergy Pharmaceuticals has promoted Marino Garcia to the newly created role of executive VP and chief strategy officer from senior VP, corporate development. He is charged with driving all business development activities, as well as leading the planning and execution of Synergy's corporate strategies and priorities.

Martin Golden
Frank Hudson
Walt Johnston
Mark Reisenauer
Kenton Stewart
ASTELLAS MAKES MANAGEMENT CHANGES

Martin Golden has been appointed to senior VP and head of marketing strategy, at Astellas, a global role responsible for developing and implementing marketing strategy for both strategic in-line products and pipeline.

In other company news, Frank Hudson has been promoted to senior VP and head of budget

and control, medical & development. Walt Johnston, Mark Reisenauer, and Kenton Stewart have been promoted to senior VPs, with responsibility for commercial activities in the United States in the areas of urology and hospital, oncology, and hospital and health systems, respectively.

► BIOTECH POOL

Dr. Roman Rubio
REVANCE THERAPEUTICS EXPANDS
LEADERSHIP TEAM

Revanche Therapeutics, a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, has added Roman Rubio, M.D., to its senior management team.

As senior VP of clinical development, Dr. Rubio leads the company's clinical development team, focusing on further accelerating the advancement of its neurotoxin development programs.

Dr. Rubio comes to Revance from Avalanche Biotechnologies, where he was senior VP of translational medicine.

Dr. David Thompson
AZURE BIOTECH NAMES
PRESIDENT

Azure Biotech, a private biotechnology company developing novel formulations of lasofoxifene, has named David Thompson, Ph.D., president. Azure is preparing to enter clinical studies in VVA with a proprietary formulation.

Dr. Thompson is a seasoned pharmaceutical executive with extensive research and clinical development experience. Most recently, at Alexion Pharmaceuticals, Dr. Thompson was the VP and global team leader responsible for the worldwide regulatory approval of Strensiq, a compound to treat hypophosphatasia.

Dr. Fatih Uckun
NANTKWEST NAMES VP OF RESEARCH AND
CLINICAL DEVELOPMENT

NantKwest, a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases, and inflammatory diseases, has appointed Fatih Uckun, M.D., as VP of research and clinical development.

Dr. Uckun is responsible for spearheading the company's overall scientific development strategy, including management of the pipeline and clinical development programs.

► BIOPHARMA POOL

Dr. Kelly Lindert
TOKAI STRENGTHENS DEVELOPMENT TEAM

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, has strengthened its development team with the addition of Kelly Lindert, M.D., as executive VP and head of development. She joins the company from Novartis Vaccines and Diagnostics, where she worked for almost eight years, most recently as the global head of development for the company's influenza vaccines program.

► EMERGING PHARMA POOL

Dr. Michael Luther
BANTAM PHARMACEUTICAL APPOINTS
PRESIDENT AND CEO

Bantam Pharmaceutical, a pharmaceutical company focused on the discovery and development of compounds to treat cancer with a focus on RNA translation, has appointed Michael Luther, Ph.D., president and CEO. Before joining as Bantam, Dr. Luther was senior VP and general manager for the discovery and development services division for Albany Molecular Research.

► CRO POOL

Dr. Judith Ng-Cashin
INC RESEARCH APPOINTS CHIEF
SCIENTIFIC OFFICER

INC Research Holdings, a global CRO, has appointed Judith Ng-Cashin, M.D., as chief scientific officer. She is responsible for leading the integration of the company's therapeutic and medical/scientific expertise for Phase I to IV clinical trials and overseeing for scientific, medical and ethical governance matters, including collaboration with key medical and scientific stakeholders. **PV**

PHARMAVOICE ARTICLE REPRINTS

Hard-copy and PDF Reprints

Reprints are a great way to showcase your press.

Hard-copy Reprints

Customized printed reproductions of your article. You can add your company logo or advertisement to increase its marketing value.

Eprints

Electronic version of a Reprint. Great for posting on your website or for e-mailing. Formatted as a pdf.



Contact Kathy Deilliis at kathy@pharmavoices.com



Clinical Trial Supply Southeast 2016



15TH-16TH JUNE, CARY, NORTH CAROLINA

Developing effective strategies and introducing novel technologies to encourage an effective international clinical trial supply chain management

Targeted specifically to the needs of the Southeast region, this conference offers attendees the opportunity to take advantage of a relevant agenda as well as meet industry colleagues and key representatives in an intimate atmosphere. **With a wide range of presentations, case studies and panel discussions**, this event will allow you to understand the full potential of the clinical supply chain and learn about the best practice methods to optimise your strategies.



Key 2016 topics include:

- Implementing an agile supply chain model that ensures flexibility and responsiveness to meet uncertain patient recruitment
- Developing contingency plans: How to respond in crisis situations to minimize disruption and ensure clinical trial supply budgets and timelines stay on track
- Uncovering effective solutions to distribution challenges to ensure your supplies arrive on time and in good condition
- U.S. Customs and Border Protection's (CBP) Pharmaceutical, Health and Chemicals Center of Excellence and Expertise (CEE)

2016 Speaker Panel includes:

- Anthony Orosz, Assistant Director, Pharmaceutical CEE, **US Customs**
- Greg Hottell, Acting Director, Global Supply Chain Management, **GSK**
- Michael Hellerstein, Director, Regulatory Affairs and Quality Systems, **GeoVax**
- Jeff Hunter, Vice President of Operations, **Novan Therapeutics**
- Tamara Monesmith, Senior Director, Manufacturing Science and Technology, **Argos Therapeutics**

Join your peers, secure your place by quoting reference **MK-OAAD**

www.arena-international.com/ctssoutheast/